Piper Jaffray increases their price target on OSI Pharmaceuticals (NASDAQ: OSIP) from $50 to $58 and maintains their Buy rating ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE